Novo Nordisk (NVO) has resolved its shortage of weight-loss drugs Ozempic and Wegovy, according to a US Food and Drug Administration website update.
The resolved shortage issue means other companies will no longer be legally allowed to use copies of semaglutide, which is the generic name for the drugs.
Shares of Novo Nordisk were up 3.9% in recent trading following the FDA's announcement, while shares of Hims & Hers Health (HIMS) were down 24%.
Price: 86.79, Change: +3.05, Percent Change: +3.64
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.